vs
Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
COASTAL FINANCIAL CORP is the larger business by last-quarter revenue ($138.0M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -5.8%). COASTAL FINANCIAL CORP produced more free cash flow last quarter ($246.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -3.6%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CCB vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $86.8M |
| Net Profit | — | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 12.4% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | -5.8% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.84 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $138.0M | $86.8M | ||
| Q3 25 | $144.7M | $67.5M | ||
| Q2 25 | $119.4M | $60.0M | ||
| Q1 25 | $139.5M | $49.3M | ||
| Q4 24 | $146.5M | $73.7M | ||
| Q3 24 | $151.1M | $58.6M | ||
| Q2 24 | $135.3M | $31.1M | ||
| Q1 24 | $148.4M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $13.6M | $-91.3M | ||
| Q2 25 | $11.0M | $-111.7M | ||
| Q1 25 | $9.7M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | $-83.5M | ||
| Q2 24 | $11.6M | $-97.1M | ||
| Q1 24 | $6.8M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 12.4% | -84.7% | ||
| Q3 25 | 12.4% | -140.7% | ||
| Q2 25 | 12.0% | -189.8% | ||
| Q1 25 | 8.4% | -245.8% | ||
| Q4 24 | 11.7% | -117.5% | ||
| Q3 24 | 10.8% | -152.1% | ||
| Q2 24 | 11.1% | -327.6% | ||
| Q1 24 | 5.9% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | 9.4% | -135.3% | ||
| Q2 25 | 9.2% | -186.2% | ||
| Q1 25 | 7.0% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | -142.7% | ||
| Q2 24 | 8.6% | -312.2% | ||
| Q1 24 | 4.6% | -15800.8% |
| Q4 25 | $0.84 | — | ||
| Q3 25 | $0.88 | — | ||
| Q2 25 | $0.71 | $-0.33 | ||
| Q1 25 | $0.63 | $-0.36 | ||
| Q4 24 | $0.95 | $-0.24 | ||
| Q3 24 | $0.97 | $-0.28 | ||
| Q2 24 | $0.84 | $-0.34 | ||
| Q1 24 | $0.50 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.0M | $698.6M |
| Total Assets | $4.7B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | — | $356.2M |
| Q4 25 | $491.0M | $698.6M | ||
| Q3 25 | $475.3M | $702.3M | ||
| Q2 25 | $461.7M | $698.5M | ||
| Q1 25 | $449.9M | $767.9M | ||
| Q4 24 | $438.7M | $710.4M | ||
| Q3 24 | $331.9M | $773.5M | ||
| Q2 24 | $316.7M | $768.5M | ||
| Q1 24 | $303.7M | $680.0M |
| Q4 25 | $4.7B | $913.2M | ||
| Q3 25 | $4.6B | $904.9M | ||
| Q2 25 | $4.5B | $907.4M | ||
| Q1 25 | $4.3B | $966.7M | ||
| Q4 24 | $4.1B | $910.4M | ||
| Q3 24 | $4.1B | $991.1M | ||
| Q2 24 | $4.0B | $964.3M | ||
| Q1 24 | $3.9B | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $254.6M | $-52.6M |
| Free Cash FlowOCF − Capex | $246.1M | $-61.9M |
| FCF MarginFCF / Revenue | 178.3% | -71.3% |
| Capex IntensityCapex / Revenue | 6.1% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $436.4M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $254.6M | $-52.6M | ||
| Q3 25 | $59.0M | $-78.7M | ||
| Q2 25 | $66.0M | $-67.4M | ||
| Q1 25 | $71.7M | $-103.7M | ||
| Q4 24 | $259.8M | $-73.3M | ||
| Q3 24 | $62.6M | $-59.0M | ||
| Q2 24 | $72.1M | $-98.4M | ||
| Q1 24 | $56.8M | $-122.3M |
| Q4 25 | $246.1M | $-61.9M | ||
| Q3 25 | $57.4M | $-89.5M | ||
| Q2 25 | $64.0M | $-74.9M | ||
| Q1 25 | $68.9M | $-109.9M | ||
| Q4 24 | $249.9M | $-77.5M | ||
| Q3 24 | $60.2M | $-61.3M | ||
| Q2 24 | $69.5M | $-98.9M | ||
| Q1 24 | $55.0M | $-126.5M |
| Q4 25 | 178.3% | -71.3% | ||
| Q3 25 | 39.7% | -132.7% | ||
| Q2 25 | 53.6% | -124.9% | ||
| Q1 25 | 49.4% | -222.8% | ||
| Q4 24 | 170.6% | -105.1% | ||
| Q3 24 | 39.8% | -104.6% | ||
| Q2 24 | 51.3% | -317.9% | ||
| Q1 24 | 37.1% | -17685.3% |
| Q4 25 | 6.1% | 10.7% | ||
| Q3 25 | 1.2% | 16.1% | ||
| Q2 25 | 1.7% | 12.4% | ||
| Q1 25 | 2.0% | 12.6% | ||
| Q4 24 | 6.8% | 5.7% | ||
| Q3 24 | 1.6% | 3.9% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 1.2% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
